TP53 and neoplasm: Several studies have described a distinctive mutational landscape in POLE-mutated EC, including alterations in TP53, PIK3CA, and CTNNB1, and a highly immunogenic tumor microenvironment which may help explain their favorable prognosis [5,14,15].